Jihyun Esther Jeon, Janet Mighty, Karen Lane, Nichol McBee, Ryan Majkowski, Steven Mayo, Daniel Hanley
{"title":"Participation of a coordinating center pharmacy in a multicenter international study.","authors":"Jihyun Esther Jeon, Janet Mighty, Karen Lane, Nichol McBee, Ryan Majkowski, Steven Mayo, Daniel Hanley","doi":"10.2146/ajhp150849","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The activities of a coordinating center pharmacy (CCP) supporting a multicenter, international clinical trial are described.</p><p><strong>Summary: </strong>Serving in a research support role comparable to that of a commercial clinical trial supply company, a CCP within the Johns Hopkins Hospital Investigational Drug Service (JHH IDS) uses its management expertise and infrastructure to support multicenter trials, such as the recently completed Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage, Phase III (CLEAR III) trial. The role of the CCP staff in supporting the CLEAR III trial was overall investigational product (IP) management through coordination of IP-related operations to ensure high-quality care for study participants at study sites in the United States and abroad. For the CLEAR III trial, the CCP coordinated IP supply activities; provided education to site pharmacists; developed study-specific documents, including pharmacy manuals; communicated with trial stakeholders, including third-party IP distributors; monitored treatment assignments; and performed quality assurance monitoring to ensure compliance with institutional, state, federal, and international regulations regarding IP procurement and storage. Acting as a CCP for a multicenter international study poses a number of operational challenges while providing opportunities for the CCP to contribute to research of global importance and enrich the skill sets of its personnel.</p><p><strong>Conclusion: </strong>The development and implementation of the CCP at JHH IDS for the CLEAR III trial included several responsibilities, such as IP supply management, communication, and database, regulatory, and finance management.</p>","PeriodicalId":75476,"journal":{"name":"American journal of orthodontics","volume":"39 1","pages":"1859-1868"},"PeriodicalIF":0.0000,"publicationDate":"2016-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188656/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of orthodontics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2146/ajhp150849","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The activities of a coordinating center pharmacy (CCP) supporting a multicenter, international clinical trial are described.
Summary: Serving in a research support role comparable to that of a commercial clinical trial supply company, a CCP within the Johns Hopkins Hospital Investigational Drug Service (JHH IDS) uses its management expertise and infrastructure to support multicenter trials, such as the recently completed Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage, Phase III (CLEAR III) trial. The role of the CCP staff in supporting the CLEAR III trial was overall investigational product (IP) management through coordination of IP-related operations to ensure high-quality care for study participants at study sites in the United States and abroad. For the CLEAR III trial, the CCP coordinated IP supply activities; provided education to site pharmacists; developed study-specific documents, including pharmacy manuals; communicated with trial stakeholders, including third-party IP distributors; monitored treatment assignments; and performed quality assurance monitoring to ensure compliance with institutional, state, federal, and international regulations regarding IP procurement and storage. Acting as a CCP for a multicenter international study poses a number of operational challenges while providing opportunities for the CCP to contribute to research of global importance and enrich the skill sets of its personnel.
Conclusion: The development and implementation of the CCP at JHH IDS for the CLEAR III trial included several responsibilities, such as IP supply management, communication, and database, regulatory, and finance management.
摘要:约翰霍普金斯医院研究药物服务部(Johns Hopkins Hospital Investigational Drug Service,JHH IDS)内的协调中心药房(CCP)扮演着与商业临床试验供应公司类似的研究支持角色,利用其管理专长和基础设施为多中心试验提供支持,例如最近完成的血栓溶解:CLEAR III)试验。在支持 CLEAR III 试验的过程中,CCP 工作人员的职责是通过协调与 IP 相关的操作,对研究产品 (IP) 进行全面管理,以确保为美国和国外研究机构的研究参与者提供高质量的治疗。在 CLEAR III 试验中,CCP 负责协调 IP 供应活动;为研究机构药剂师提供教育;制定特定研究文件,包括药房手册;与试验利益相关方沟通,包括第三方 IP 分销商;监控治疗分配;以及执行质量保证监控,以确保符合机构、州、联邦和国际有关 IP 采购和储存的规定。作为一项多中心国际研究的 CCP,在为 CCP 提供机会为具有全球重要性的研究做出贡献并丰富其人员的技能组合的同时,也带来了许多运营方面的挑战:JHH IDS 为 CLEAR III 试验开发和实施的 CCP 包括多项职责,如知识产权供应管理、沟通以及数据库、监管和财务管理。